Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study)

Next Previous
Trial Profile

An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary) ; Capecitabine
  • Indications Adenocarcinoma; Colon cancer; Rectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SOLSTICE
  • Sponsors Institut de Recherches Internationales Serviers

    • Most Recent Events

    • 06 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top